Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Retained Earnings (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Retained Earnings for 4 consecutive years, with $144039.0 as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 3.47% to $144039.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $144039.0, a 3.47% increase, with the full-year FY2024 number at $135471.0, changed 0.07% from a year prior.
  • Retained Earnings was $144039.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$44.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $144039.0 in Q3 2025 to a low of -$44.1 million in Q2 2025.
  • A 4-year average of -$13.3 million and a median of $81386.0 in 2023 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 100.39% in 2025; the steepest drop was 21.52% in 2025.
  • 60 Degrees Pharmaceuticals' Retained Earnings stood at $73708.0 in 2022, then soared by 83.92% to $135561.0 in 2023, then fell by 0.07% to $135471.0 in 2024, then grew by 6.32% to $144039.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Retained Earnings are $144039.0 (Q3 2025), -$44.1 million (Q2 2025), and $125567.0 (Q1 2025).